Skip to main content

abelacimab

abelacimab: 4 clinical trials tracked.

abelacimab evidence translation

What we can confirm

4 tracked trials

No verified listed developer

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about abelacimab, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence2 indications · 2 study sponsors
Clinical Trials (4)

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)

NCT07739888·Phase 3·NVS
Not yet recruiting

Primary endpoint: Time to first ISTH major Bleeding events

Interventionalopen2,500 targetStarted 2027-12Completion 2030-12Novartis Pharmaceuticals

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)

NCT05712200·Phase 3
Recruiting

Primary endpoint: Efficacy: Time to first event of ischemic stroke or systemic embolism (SE)

InterventionalRandomizeddouble2,500 targetStarted 2022-12Completion 2027-1250 sites · United StatesAnthos Therapeutics, Inc.

A Multicenter, Randomized, Open-label, Blinded Endpoint Evaluation, Phase 3 Study Comparing the Effect of Abelacimab vs. Dalteparin on Venous Thromboembolism (VTE) Recurrence and Bleeding in Patients With GI/GU Associated VTE

NCT05171075·Phase 3·DNTH
Terminated

Primary endpoint: Time to first event of centrally adjudicated VTE recurrence

InterventionalRandomizedsingle417 targetStarted 2022-09Completion 2026-0450 sites · Australia, Austria, Canada, China…Anthos Therapeutics, Inc.

A Multicenter, Randomized, Open-label, Blinded Endpoint Evaluation, Phase 3 Study Comparing the Effect of Abelacimab Relative to Apixaban on Venous Thromboembolism (VTE) Recurrence and Bleeding in Patients With Cancer Associated VTE

NCT05171049·Phase 3·DNTH
Terminated

Primary endpoint: Time to first event of centrally adjudicated VTE recurrence

InterventionalRandomizedsingle1,150 targetStarted 2022-05Completion 2026-0250 sites · Australia, Austria, Canada, China…Anthos Therapeutics, Inc.